Published in Physician Law Weekly, May 3rd, 2006
RECIST defines an objective response as a patient having a complete or partial response, with a partial response being at least a 50% reduction in total tumor size. Based on this preliminary data, the company will not enroll patients in stage 2 and expects to begin dosing patients in a Europe-based phase III trial for the second line treatment of colorectal...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.